Avalyn Pharma Inc.’s Lock-Up Period Will Expire Tomorrow (NASDAQ:AVLN)

Avalyn Pharma’s (NASDAQ:AVLN) lock-up period is set to end on Tuesday, October 27th. Avalyn Pharma had issued 16,666,667 shares in its IPO on April 30th. The total size of the offering was $300,000,006 based on an initial share price of $18.00. After the expiration of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Raymond James Financial assumed coverage on shares of Avalyn Pharma in a research report on Friday, October 2nd. They set an “outperform” rating and a $60.00 price target for the company. Weiss Ratings initiated coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They issued a “sell (d+)” rating for the company. Wall Street Zen cut shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Finally, Morgan Stanley upped their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Avalyn Pharma Price Performance

Shares of Avalyn Pharma stock opened at $26.04 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The company has a market capitalization of $1.15 billion and a price-to-earnings ratio of -1.14. Avalyn Pharma has a fifty-two week low of $22.24 and a fifty-two week high of $40.17. The company has a 50-day moving average price of $31.37.

Avalyn Pharma (NASDAQ:AVLN) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.05. As a group, equities research analysts anticipate that Avalyn Pharma will post -3.86 earnings per share for the current year.

Institutional Investors Weigh In On Avalyn Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Montanova Capital LLC bought a new position in Avalyn Pharma during the second quarter worth $82,402,000. Braidwell LP bought a new stake in Avalyn Pharma during the second quarter valued at $26,382,000. State Street Corp bought a new stake in Avalyn Pharma during the second quarter valued at $10,501,000. Bank of New York Mellon Corp acquired a new stake in shares of Avalyn Pharma during the second quarter worth $1,321,000. Finally, Manchester Capital Management LLC acquired a new stake in shares of Avalyn Pharma during the third quarter worth $36,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.